Similar examples of SGLT2-is administration, apart from those already mentioned above, include the studies by Kuchay et al. [52], Chehrehgosha et al. [53] and Taheri et al. [54], which showed a benefit in hepatic steatosis from the administration of empagliflozin, the studies by Eriksson et al. [55] and Kurinami et al. [56], which showed a similar benefit from the administration of dapagliflozin, as well as the study by Nishimiya et al. [57], in which canagliflozin was administered. The gene discussed is SLC5A2; the disease is fatty liver disease.